Annual Operating Profit
-$569.21 M
+$79.71 M+12.28%
December 31, 2023
Summary
- As of February 7, 2025, RARE annual operating income is -$569.21 million, with the most recent change of +$79.71 million (+12.28%) on December 31, 2023.
- During the last 3 years, RARE annual operating profit has fallen by -$239.09 million (-72.43%).
- RARE annual operating profit is now -8575.63% below its all-time high of -$6.56 million, reached on December 31, 2011.
Performance
RARE Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Profit
-$131.99 M
-$15.63 M-13.43%
September 30, 2024
Summary
- As of February 7, 2025, RARE quarterly operating income is -$131.99 million, with the most recent change of -$15.63 million (-13.43%) on September 30, 2024.
- Over the past year, RARE quarterly operating profit has increased by +$13.11 million (+9.04%).
- RARE quarterly operating profit is now -2721.44% below its all-time high of -$4.68 million, reached on December 31, 2012.
Performance
RARE Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM Operating Profit
-$535.74 M
+$13.11 M+2.39%
September 30, 2024
Summary
- As of February 7, 2025, RARE TTM operating income is -$535.74 million, with the most recent change of +$13.11 million (+2.39%) on September 30, 2024.
- Over the past year, RARE TTM operating profit has increased by +$57.04 million (+9.62%).
- RARE TTM operating profit is now -11352.42% below its all-time high of -$4.68 million, reached on December 31, 2012.
Performance
RARE TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Profit Formula
Operating Profit = Gross Profit − Operating Expenses
RARE Operating Profit Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +12.3% | +9.0% | +9.6% |
| 3 y3 years | -72.4% | -46.9% | -42.8% |
| 5 y5 years | -53.3% | -11.8% | -26.3% |
RARE Operating Profit Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -49.1% | +12.3% | -28.7% | +41.4% | -40.3% | +20.4% |
| 5 y | 5-year | -72.4% | +12.3% | -162.3% | +41.4% | -69.5% | +20.4% |
| alltime | all time | -8575.6% | +12.3% | -2721.4% | +41.4% | <-9999.0% | +20.4% |
Ultragenyx Pharmaceutical Operating Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$131.99 M(+13.4%) | -$535.74 M(-2.4%) |
| Jun 2024 | - | -$116.36 M(-29.6%) | -$548.85 M(-5.4%) |
| Mar 2024 | - | -$165.35 M(+35.5%) | -$580.45 M(+2.0%) |
| Dec 2023 | -$569.21 M(-12.3%) | -$122.05 M(-15.9%) | -$569.21 M(-4.0%) |
| Sep 2023 | - | -$145.10 M(-1.9%) | -$592.79 M(-11.9%) |
| Jun 2023 | - | -$147.96 M(-4.0%) | -$672.76 M(+1.0%) |
| Mar 2023 | - | -$154.10 M(+5.8%) | -$666.39 M(+2.7%) |
| Dec 2022 | -$648.92 M(+70.0%) | -$145.63 M(-35.3%) | -$648.92 M(+7.1%) |
| Sep 2022 | - | -$225.07 M(+59.0%) | -$605.86 M(+28.7%) |
| Jun 2022 | - | -$141.59 M(+3.6%) | -$470.62 M(+14.3%) |
| Mar 2022 | - | -$136.63 M(+33.2%) | -$411.80 M(+7.9%) |
| Dec 2021 | -$381.74 M(+15.6%) | -$102.56 M(+14.2%) | -$381.74 M(+1.7%) |
| Sep 2021 | - | -$89.83 M(+8.5%) | -$375.25 M(+11.8%) |
| Jun 2021 | - | -$82.78 M(-22.3%) | -$335.74 M(+6.2%) |
| Mar 2021 | - | -$106.57 M(+10.9%) | -$316.02 M(-4.3%) |
| Dec 2020 | -$330.12 M(-22.2%) | -$96.08 M(+91.0%) | -$330.12 M(+0.5%) |
| Sep 2020 | - | -$50.31 M(-20.2%) | -$328.49 M(-17.1%) |
| Jun 2020 | - | -$63.05 M(-47.7%) | -$396.20 M(-11.1%) |
| Mar 2020 | - | -$120.67 M(+27.8%) | -$445.62 M(+5.1%) |
| Dec 2019 | -$424.17 M(+14.2%) | -$94.45 M(-20.0%) | -$424.17 M(+1.0%) |
| Sep 2019 | - | -$118.03 M(+4.9%) | -$420.06 M(+7.2%) |
| Jun 2019 | - | -$112.47 M(+13.4%) | -$391.67 M(+4.7%) |
| Mar 2019 | - | -$99.21 M(+9.8%) | -$374.10 M(+0.7%) |
| Dec 2018 | -$371.37 M | -$90.34 M(+0.8%) | -$371.37 M(-1.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$89.65 M(-5.5%) | -$377.87 M(+1.6%) |
| Jun 2018 | - | -$94.90 M(-1.6%) | -$371.93 M(+4.6%) |
| Mar 2018 | - | -$96.49 M(-0.4%) | -$355.48 M(+8.1%) |
| Dec 2017 | -$328.94 M(+32.6%) | -$96.83 M(+15.7%) | -$328.94 M(+8.7%) |
| Sep 2017 | - | -$83.71 M(+6.7%) | -$302.66 M(+6.3%) |
| Jun 2017 | - | -$78.44 M(+12.1%) | -$284.73 M(+7.7%) |
| Mar 2017 | - | -$69.95 M(-0.8%) | -$264.34 M(+6.6%) |
| Dec 2016 | -$248.01 M(+67.9%) | -$70.55 M(+7.2%) | -$248.01 M(+6.2%) |
| Sep 2016 | - | -$65.78 M(+13.3%) | -$233.62 M(+12.4%) |
| Jun 2016 | - | -$58.05 M(+8.3%) | -$207.77 M(+15.5%) |
| Mar 2016 | - | -$53.62 M(-4.5%) | -$179.86 M(+21.7%) |
| Dec 2015 | -$147.74 M(+160.2%) | -$56.16 M(+40.6%) | -$147.74 M(+36.1%) |
| Sep 2015 | - | -$39.94 M(+32.5%) | -$108.52 M(+28.5%) |
| Jun 2015 | - | -$30.14 M(+40.2%) | -$84.42 M(+24.3%) |
| Mar 2015 | - | -$21.50 M(+26.9%) | -$67.94 M(+19.7%) |
| Dec 2014 | -$56.78 M(+75.9%) | -$16.94 M(+7.0%) | -$56.78 M(+15.0%) |
| Sep 2014 | - | -$15.84 M(+15.9%) | -$49.36 M(+19.6%) |
| Jun 2014 | - | -$13.66 M(+32.1%) | -$41.29 M(+15.1%) |
| Mar 2014 | - | -$10.34 M(+8.5%) | -$35.87 M(+11.1%) |
| Dec 2013 | -$32.28 M(+101.9%) | -$9.53 M(+22.7%) | -$32.28 M(+17.7%) |
| Sep 2013 | - | -$7.76 M(-5.9%) | -$27.43 M(+39.5%) |
| Jun 2013 | - | -$8.25 M(+22.2%) | -$19.67 M(+72.2%) |
| Mar 2013 | - | -$6.75 M(+44.2%) | -$11.43 M(+144.2%) |
| Dec 2012 | -$15.98 M(+143.6%) | -$4.68 M | -$4.68 M |
| Dec 2011 | -$6.56 M | - | - |
FAQ
- What is Ultragenyx Pharmaceutical annual operating income?
- What is the all time high annual operating profit for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical annual operating profit year-on-year change?
- What is Ultragenyx Pharmaceutical quarterly operating income?
- What is the all time high quarterly operating profit for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical quarterly operating profit year-on-year change?
- What is Ultragenyx Pharmaceutical TTM operating income?
- What is the all time high TTM operating profit for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical TTM operating profit year-on-year change?
What is Ultragenyx Pharmaceutical annual operating income?
The current annual operating profit of RARE is -$569.21 M
What is the all time high annual operating profit for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high annual operating income is -$6.56 M
What is Ultragenyx Pharmaceutical annual operating profit year-on-year change?
Over the past year, RARE annual operating income has changed by +$79.71 M (+12.28%)
What is Ultragenyx Pharmaceutical quarterly operating income?
The current quarterly operating profit of RARE is -$131.99 M
What is the all time high quarterly operating profit for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high quarterly operating income is -$4.68 M
What is Ultragenyx Pharmaceutical quarterly operating profit year-on-year change?
Over the past year, RARE quarterly operating income has changed by +$13.11 M (+9.04%)
What is Ultragenyx Pharmaceutical TTM operating income?
The current TTM operating profit of RARE is -$535.74 M
What is the all time high TTM operating profit for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high TTM operating income is -$4.68 M
What is Ultragenyx Pharmaceutical TTM operating profit year-on-year change?
Over the past year, RARE TTM operating income has changed by +$57.04 M (+9.62%)